ClinicalTrials.gg
RecruitingNCT03178149Updated Nov 19, 2026

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

A Phase 1 interventional study of ASP7317 and tacrolimus in Age-Related Macular Degeneration, sponsored by Astellas Institute for Regenerative Medicine. Recruiting at 20 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionGeographic AtrophyRegistry: Macular DegenerationReclassifiedWhy we changed it
Registry
Macular Degeneration — the first condition term the registry derived for this study.
ClinicalTrials.gg
Geographic Atrophy
Why
  1. The study's title name Geographic Atrophy, a narrower term within Macular Degeneration.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2019; still recruiting 7 years 9 months later.
Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
75th of 107
42 · median 98
Started
2019
with 9 others
Phase 1
16 of 131
3 open now
Primary completion
2027-12
later than 19 of 44 live
Registered
49th of 131
by date
Lead sponsor
3 of 131
Astellas Institute for Regenerative Medicine

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 75th largest by planned enrollment of the 107 interventional ones that give a count, is one of 10 that started in 2019, is one of 16 in phase 1, reaches primary completion later than 19 of the 44 other live ones, and was the 49th registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

30 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Geographic Atrophy studies recruiting now, 32 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry AMD. The advanced stage of dry AMD causes vision loss. This is known as geographic atrophy. AMD makes everyday tasks like reading or driving difficult.

ASP7317 is a potential new treatment for people with AMD. ASP7317 are human stem cells which have changed into cells found in the retina. ASP7317 is injected under the macula. It is hoped that ASP7317 will replace some of the damaged cells in the macula and improve vision for people with dry AMD.

Before ASP7317 is available as a treatment, the researchers need to check its safety and how well it is tolerated. They will also check for signs of improved vision. People taking part in this study will be older people who have geographic atrophy caused by dry AMD.

This is an open-label study. This means that people in this study and clinic staff will know that people will receive ASP7317. There will be 3 doses of ASP7317. These are low, medium and high numbers of cells. ASP7317 will be injected under the macula after the person is given either a local or a general anesthetic. To prevent the body from rejecting the cells, people will take tablets of tacrolimus a few days before receiving ASP7317 for up to a few weeks afterwards. Other medicines will be taken during this time to stop infections.

There will be 2 groups in the study. Group 1 will be people with severe vision loss and Group 2 will be people with moderate vision loss. There will be different small groups of people within Group 1 and Group 2, with each small group receiving 1 of the 3 doses of ASP7317.

Different small groups of people within Group 1 and Group 2 will receive lower to higher doses of ASP7317. Each small group will only receive 1 dose. Group 1 will start treatment first. At each dose, a medical expert panel will check the results of the first person in the group to decide if the rest of the group will receive the same dose. Then, the panel will decide if more people may receive the same dose or if the next group may receive the next highest dose. The panel will use the results from the lower dose of Group 1 to decide when Group 2 starts treatment (also at the lower dose). The panel will also use the results of the middle and higher doses in Group 1 to decide when and how many people in Group 2 can receive these doses. During the study, people will visit the clinic several times for up to 12 months (1 year).

During all visits, the study doctors will check for any medical problems after receiving ASP7317. Vital signs will be checked a few days before treatment with ASP7317 and up to about a month afterwards. Vital signs include blood pressure, pulse, and temperature. At some visits, the study doctors will also take blood samples for blood tests. At most visits, people will have eye tests and have different images, scans, and measurements taken. This could be for the affected eye or both eyes, depending on the test. People can visit the clinic extra times, if needed.

Read the detailed description

The study consists of the following periods: Screening (up to 60 days) and the Study Period (52 weeks post treatment).

03

Conditions studied

  • Age-Related Macular Degeneration

Browse trials for

Keywords

  • Geographic Atrophy
  • Age-related Macular Degeneration
  • ASP7317
04

In context

Geographic Atrophy Reclassified

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

This study's planned enrollment of 42 is below the median of 70 across 141 interventional studies indexed under Geographic Atrophy.

Browse Geographic Atrophy studies →

Lead sponsor

Astellas Institute for Regenerative Medicine is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc.

Compared within Geographic Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Macular Degeneration. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

General Inclusion Criteria

  • Participant must be willing to take tacrolimus and willing to discontinue any medications that have a known strong interaction with tacrolimus.
  • Participant is able and willing to undertake all scheduled visits and assessments up to the week 52 visit.
  • Participant who is taking an antidepressant must be on a stable and effective dosage and must be willing to take it reliably for as long as it is required.
  • Participant must be willing and medically suitable to undergo monitored anesthesia care during the vitrectomy and subretinal injection.
  • Participant agrees to conform to local and institutional policies regarding active COVID-19 infections.
  • Participant agrees not to participate in another interventional study until the 52-week visit has been completed.
  • Female participant is not pregnant or at least 1 of the following conditions apply:

    • Not a woman of (WOCBP)
    • WOCBP who agrees to follow the guidance from the time of through at least 52 weeks after product (IP) administration.
  • Female participant must agree not to breastfeed starting at screening and throughout the study period and for 52 weeks after IP administration.
  • Female participant must not donate ova starting at first dose of IP and throughout the study period and for 52 weeks after IP administration.
  • Male participant with female partner(s) of childbearing potential (including breastfeeding partner) must agree to use contraception throughout the treatment period and for 52 weeks after IP administration.
  • Male participant must not donate sperm during the treatment period and for 52 weeks after IP administration.
  • Male participant with pregnant partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy throughout the study period and for 52 weeks after IP administration.

Ocular Inclusion Criteria: Study Eye (Both Groups 1 and 2)

  • Participant has bilateral AMD and geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) in the study eye. GA is defined as sharply demarcated areas of loss of the retinal pigment epithelial/epithelium (RPE). While having bilateral GA remains the preferred enrollment criterion, it is not a requirement and GA only in the study eye is admissible, as long as both eyes exhibit AMD.
  • Participant has no known history of choroidal neovascularization (CNV) (wet AMD) in either eye prior to enrollment in the trial and no evidence of prior or active CNV with optical coherence tomographyangiography (OCT-A) or indocyanine green angiography (ICG-A), as assessed by the reading center.
  • Participant has absence of exudation as assessed by fluorescein angiography (FA) and spectral domain-optical coherence tomography (SD-OCT).
  • Participant has sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging.
  • Participant is pseudophakic.

Ocular Inclusion Criteria: Study Eye (Group 1 only)

  • For cohort 1, the participant has a BCVA between light perception and \</=23 Early Treatment Diabetic Retinopathy study (ETDRS) letters at the screening visit. For cohorts 2 and 3, the participant has a BCVA score between 15 (>/= 20/500) and 37 (\</=20/200) ETDRS letters at the screening visit.
  • Participant has the total GA area \</=30.5 mm\^2 (\</=12 disc areas [DA]).

Ocular Inclusion Criteria: Study Eye (Group 2 only)

  • Participant has BCVA score between 38 (>20/200) and 65 (\</=20/50) ETDRS letters during the screening visit.
  • Participant has the total GA area of >/= 2.54 mm\^2 and \</= 20.4 mm\^2 (>/=1 and \</=8 DA, respectively) and must reside completely within the fundus autofluorescence (FAF) imaging field (Field 2 to 30 degree image centered on the fovea).
  • Participant has a difference in mean mesopic sensitivity \</=2 dB between 2 tests at screening. If not \</=2 dB, a third test may be conducted and mean values between the second and third assessments must be \</=2 dB.

Exclusion criteria

Exclusion Criteria:

General Exclusion Criteria

  • Participant has a history of recurrent varicella zoster virus (VZV) infection or a clinical diagnosis of VZV infection within 4 weeks of the baseline visit or positive anti-VZV immunoglobulin M (IgM). Being positive for immunoglobulin G (IgG), indicative of a past infection (or vaccination), is not an exclusionary criterion.
  • Participant has a history of recurrent cytomegalovirus (CMV) infection or a clinical diagnosis of CMV infection within 4 weeks of the baseline visit or positive anti-CMV IgM. Being positive for IgG, indicative of a past infection, is not an exclusionary criterion.
  • Participant has a positive tuberculosis (TB) test during the screening period by an interferon gamma release assay (e.g., QuantiFERON) within the 6 months prior to the screening. If a participant has tested negative for TB within the 6 months prior to the screening visit, retesting is not required unless clinically indicated.
  • Participant has a history or suspected active infection of toxoplasmosis or presence of elevated immunoglobulin M (IgM) toxoplasmosis titer within 4 weeks of the baseline visit.
  • Participant has an active infection (ocular or non-ocular) requiring the prolonged or chronic use of antimicrobial or anti-infective agents.
  • Participant has a current or history of malignancy within the past 5 years, except non- basal or squamous cell carcinoma or keratoacanthoma or Bowen's disease or carcinoma-in-situ of the cervix that has been successfully treated.
  • Participant has a history of a solid organ or bone marrow transplant.
  • Participant has any condition that would prohibit the use of systemic with tacrolimus.
  • Participant is receiving or has received any immunosuppressive therapy (IMT) (other than topical, inhaled or low dose systemic use not exceeding 7.5 mg of prednisone daily [or equivalent]) within 6 weeks or 5 plasma half-lives, whichever is longer, prior to the administration of adjunct study medications.
  • Participant has a history of myocardial infarction in previous 12 months and whose disease is either unstable and/or symptomatic (e.g., angina, dyspnea, etc.).
  • Participant has (ECG) results that are and could either jeopardize the safety of the participant, impact the participant's ability to comply with study visit schedule or impact the validity of the study results. Participants with a mean Fridericia- interval of > 430 ms (for males) and > 450 ms (for females) at screening must be cleared by a cardiologist prior to the baseline visit.
  • Participant has a study day diastolic blood pressure > 95 mmHg, at either the screening or baseline visit. Study day blood pressure is defined as the average of the second and third readings at a study visit. If the study day blood pressure exceeds the limits, 1 additional triplicate can be taken.
  • Participant has an estimated (eGFR) of \</= 30 mL/min, calculated by the chronic kidney disease epidemiology collaboration (CKD-EPI) equation.
  • Participant has an (ALT), aspartate aminotransferase (AST) or gamma- glutamyltransferase (GGT) and total (TBL) >/= 2 times the (ULN).
  • Participant has severe anemia ( \< 9 g/dL [male] or hemoglobin \< 8 g/dL [female]), leucopenia (white blood cell count \< 2500/mm\^3), thrombocytopenia ( count \< 80000/mm\^3) or polycythemia (hematocrit > 54% [male] or hematocrit > 49% [female]).
  • Participant has a > 8.5%.
  • Participant has a clinically significant coagulopathy (i.e., [aPTT] >/= 1.5 times the ULN and/or prothrombin time adjusted for the international normalized ratio [PT-INR] >/=2.0).
  • Participant has serology results indicative of having syphilis, Lyme disease, infection or active infection with hepatitis A virus (HAV), virus (HBV), virus (HCV), or varicella-zoster virus (VZV).
  • Participant has a history of familial adenomatous polyposis or inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
  • Participant has a history of allergic reaction to mydriatics or fluorescein.
  • Participant has a history of gene therapy or cell transplant therapy, including ASP7316, in a prior clinical study.
  • Participant has participated in any studies of an drug or procedure (excluding vitamins and minerals for AMD studies) within 12 weeks prior to the screening visit, except as noted in below criterion.
  • Participant has participated with the study eye in any trial of a now FDA-approved complement inhibitor and/or has received an FDA approved complement inhibitor injection in the study eye within 24 weeks of the screening visit. After a of 24 or more weeks, participants previously treated with a complement inhibitor will be eligible for participation, but participants will not be allowed to resume receiving any approved or investigational complement inhibitor in the study eye until the completion of the 52-week follow up period of the A7317-CL-0003 trial. Use of an FDA-approved complement inhibitor in the fellow, non-study eye is allowable.
  • Participant is unwilling to discontinue or avoid any inducers (e.g., rifampin, rifabutin, phenytoin, carbamazepine, phenobarbital, St John's Wort) or participant is unwilling to discontinue or avoid protease inhibitors (e.g., nelfinavir, telaprevir, boceprevir), direct Factor Xa inhibitors, direct thrombin inhibitors, verapamil, diltiazem or erythromycin while taking tacrolimus.
  • Participant has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, opiates, cocaine, phencyclidine and methadone), unless the drug is taken for a documented medical condition and under the supervision of a physician.

Ocular Exclusion Criteria - Study Eye

  • Participant has macular degeneration due to causes other than AMD (e.g., Stargardt disease, cone rod dystrophy, toxic maculopathies, etc.)
  • Participant has developed CNV (wet AMD), also known as exudative AMD in either eye.
  • Participant has foveal sparing as determined by the presence of potentially viable photoreceptors, as evidenced by presence of an intact ellipsoid zone (EZ) \</= 250 microns from the foveal center, based on reading center assessments at the screening visit.
  • Participant has a history of vitrectomy or submacular surgery, or any surgical intervention for AMD. Participants with a history of non-AMD-related surgical interventions (other than vitrectomy and submacular surgery) are potentially eligible if they meet all other inclusion/exclusion criteria.
  • Participant has prior treatment with photodynamic therapy (e.g., Visudyne®), intraocular external-beam radiation therapy or transpupillary thermotherapy.
  • Participant has a history of previous laser photocoagulation for choroidal neovascularization (CNV), diabetic macular edema, retinal vein occlusion and proliferative diabetic retinopathy.
  • Participant has an abnormality of vitreoretinal interface (e.g., tractional epiretinal membrane (ERM)), which can interfere with measurement of macular thickness or with the potential for macular structural damage.
  • Participant has a history of cystoid macular edema, retinal vascular occlusion, central serous chorioretinopathy, macular hole or retinoschisis in the study eye.
  • Participant has peripheral holes or other peripheral retinal lesions that are considered of rhegmatogenous potential (that is, with a risk of causing retinal detachment).
  • Participant has active or history of intraocular inflammation such as uveitis, chorioretinitis and optic neuropathy (other than glaucoma).
  • Participant has presence of an ocular toxoplasmosis scar.
  • Participant has nevus of Ota (oculodermal melanocytosis), a pigmented choroidal lesion showing characteristics associated with high risk of malignancy (e.g., elevated lesion) or a choroidal nevus in the macula.
  • Participant has pathologic myopia defined as a spherical equivalent of > 8.00 diopters or axial length > 28 mm at the screening visit, or myopic macular degeneration or posterior staphyloma.
  • Participant has glaucoma with uncontrolled intraocular pressure (IOP) (defined as IOP > 30 mmHg despite treatment with anti-glaucoma medication) or is using more than 2 agents to control IOP or a history of glaucoma-filtering surgery.
  • Participant has a history of corneal transplantation.
  • Participant has monocular vision; no light perception in the fellow eye or anophthalmic in the fellow eye.
  • Participant has a to pupil dilation.
  • Participant has any other ocular condition that can interfere with the assessment of imaging data.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    ASP7317 Dose Escalation/ Expansion (Group 1: Severe Vision Loss)

    Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 1: low cells/dose; cohort 2: medium cells/dose; cohort 3: high cells/dose). Optional Expansion cohorts 3b will be opened after cohort 3 has been filled and 2b will be opened only if necessary. Dose levels for the expansion cohort will align with dose levels in escalation cohorts. Sentinel dosing will be required for each dose level. After the first participant in each dose cohort in Group 1 is dosed and followed for 4 weeks, the Independent Data Monitoring Committee (IDMC) will review the 4-week safety data and recommend if the second and third participants in Group 1 dose cohort may be treated. The IDMC recommendation to progress to the next dosing cohort will be based on 4-week follow-up safety review of the second and third participants in the preceding dose cohort. Participants will receive tacrolimus and other medicines to stop infection.

    Drug: ASP7317 · Drug: tacrolimus · Drug: trimethoprim-sulfamethoxazole · Drug: Acyclovir · Drug: Nystatin

  • Experimental
    ASP7317 Dose Escalation/ Expansion (Group 2: Moderate Vision Loss)

    Successive cohorts of participants (3 participants each) will be given escalating doses (cohort 4: low cells/dose; cohort 5: medium cells/dose; cohort 6: high cells/dose). Optional Expansion cohorts 5b and 6b will be opened after cohorts 5 and 6 have been filled. Dose levels for the expansion cohorts will align with dose levels in escalation cohorts. Cohort 4 (low cells/dose) dosing may begin after the IDMC recommendation to begin dosing in Group 1 cohort 2 (medium cells/dose). Cohort 5 (medium cells/dose) dosing may begin after IDMC review of the 4- week safety data of the first participant in Group 1 cohort 2 (medium cells/dose). Cohort 6 (high cells/dose) dosing may begin after IDMC review of 4-week safety data of the first participant in Group 1 cohort 3 (high cells/dose). Dosing in cohort 5 and 6 can only begin after the IDMC review and the completion of the preceding cohort. Participants will receive tacrolimus and other medicines to stop infection.

    Drug: ASP7317 · Drug: tacrolimus · Drug: trimethoprim-sulfamethoxazole · Drug: Acyclovir · Drug: Nystatin

Interventions

  • DrugASP7317

    subretinal injection

  • oral

    Also known as: FK506, Prograf®

  • Drugtrimethoprim-sulfamethoxazole

    oral

    Also known as: TMP/SMX

  • oral

  • oral

07

What researchers measure

Primary outcomes

  1. Safety as assessed by incidence, frequency and severity of treatment emergent adverse events (TEAES)

    Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). An Adverse Event is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of ASP7317, the adjunct study medications and the study procedures, whether or not considered related to ASP7317, the adjunct study medications and the study procedures. A Treatment Emergent Adverse Event (TEAE) is defined as an AE beginning or worsening in severity after starting administration of the adjunct study medication.

    Time frame: Up to 52 Weeks

  2. Safety as assessed by incidence, frequency and severity of Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in congenital anomaly or birth defect or other medically important events.

    Time frame: Up to 52 Weeks

  3. Safety assessed by Adverse Events (AEs) of special interest

    AEs of special interest include: ectopic or proliferative cell growth (retinal pigment epithelial/epithelium (RPE) or non-RPE) with adverse clinical consequence; any new diagnosis of an immune-mediated disorder; any new cancer, irrespective of prior history; unexpected, clinically significant AEs possibly related to the cell transplant procedure; immunosuppressive therapy (IMT) or ASP7317 (e.g., graft failure or rejection).

    Time frame: Up to 52 Weeks

  4. Number of participants with cellular graft failure or rejection

    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.

    Time frame: Up to 52 Weeks

  5. Incidence of cellular graft failure or rejection

    Evidence of cellular graft failure or rejection will be assessed by best corrected visual acuity (BCVA), slit lamp examination, dilated indirect ophthalmoscopy, fundus photographs, spectral domain-optical coherence tomography (SD-OCT) and fluorescein angiography (FA), when performed.

    Time frame: Up to 52 Weeks

Secondary outcomes

  1. Mean change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Time frame: Baseline, Weeks 26 and 52/End of Study (EOS)

  2. Mean percent change from baseline in area of Geographic Atrophy (GA) (mm^2) in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Time frame: Baseline, Weeks 26 and 52/End of Study (EOS)

  3. Mean change from baseline in the square root transformation of Geographic Atrophy (GA) area in study eye and fellow eye

    GA will be measured by blue-light fundus autofluorescence (FAF) (definitely decreased autofluorescence (DDAF)) and spectral domain-optical coherence tomography (SD-OCT) (area of ellipsoid zone (EZ) defect, area of outer nuclear layer (ONL) defect).

    Time frame: Baseline, Weeks 26 and 52/End of Study (EOS)

  4. Mean change from baseline in best corrected visual acuity (BCVA) score in study eye and fellow eye

    BCVA will be measured by an assessor certified to use the Early Treatment of Diabetic Retinopathy Study (ETDRS) method. The BCVA score (in letter units) will be reported.

    Time frame: Baseline, Weeks 1, 4, 6, 8, 12, 16, 26 and 52/End of Study (EOS)

  5. Mean change from baseline in mean sensitivity

    Mean sensitivity is the mean over all point-wise sensitivity zones. Point-wise sensitivity will be estimated using imaging measures obtained across all zones, treatment area and remote zone.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  6. Mean change from baseline in point wise sensitivity (PWS) in treatment zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the treatment zone as assessed by imaging criteria. Treatment zone in the study eye is defined as the area that corresponds to the subretinal bleb area identified by the day 0 fundus photograph.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  7. Mean change from baseline in PWS in extended treatment zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the extended treatment zone as assessed by imaging criteria. Treatment zone in the study eye is defined as the area that corresponds to the subretinal bleb area identified by the day 0 fundus photograph. Equivalent treatment zone in the fellow eye is defined as the quadrant that meets the criteria for the location for ASP7317 injection, as determined by the investigator.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  8. Mean change from baseline in PWS in remote zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the remote zone as assessed by imaging criteria. Remote zone is defined as retina outside and opposite to the treatment zone.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  9. Mean change from baseline in PWS in extended remote zone

    Point-wise sensitivity will be measured using sensitivity results obtained in the extended remote zone as assessed by imaging criteria. Remote zone is defined as retina outside and opposite to the treatment zone.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  10. Mean change from baseline in number of scotomatous points

    Scotomatous points (loci) will be measured using imaging measures. The number of scotomatous points is the total number of points that were not seen (\<0 dB loci).

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  11. Mean change from baseline in fixation stability (95% bivariate contour ellipse area (BCEA))

    Fixation Stability will be measured using imaging measures obtained during the microperimetry testing session, categorized as stable, relatively unstable and unstable. Categorization of stability based on % of fixation points within a specified diameter circle centered in the gravitational center of all fixation points. Stable-More than 75% of fixation points located within 2 degree diameter circle. Relatively Unstable-Less than 75% of fixation points located within 2 degrees diameter circle, but more than 75% of fixation points located within 4 degree diameter circle. Unstable-Less than 75% of fixation points located within 4 degree diameter circle.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

  12. Mean change from baseline in distance of preferred retinal locus (PRL) from Fovea

    Distance of PRL from Fovea will be measured using imaging measures obtained during the microperimetry testing session. Participant with central vision loss obtain visual information with a preferred eccentric retinal area for visual tasks because of their central scotoma. This area is called the preferred retinal locus.

    Time frame: Baseline, Weeks 4, 12, 26 and 52/End of Study (EOS)

08

Study locations

13 of 20 sites recruiting
  • Retinal Consultants of Arizona LTD, Retinal Research Institute
    Phoenix, Arizona 85053, United States
    Withdrawn

    Not enrolling at this site.

  • Jules Stein Eye Institute
    Los Angeles, California 90095, United States
    Recruiting
  • Stanford University Byers Eye Institute
    Palo Alto, California 94303, United States
    Recruiting
  • Kaiser Permanente Riverside Medical Center
    Riverside, California 92505, United States
    Recruiting
  • Retina Consultants of Southwest Florida & National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
    Withdrawn

    Not enrolling at this site.

  • Retina Specialty Institute
    Pensacola, Florida 35203, United States
    Recruiting
  • Emory University Eye Center
    Atlanta, Georgia 30322, United States
    Recruiting
  • University Retina and Macula Associates
    Oak Forest, Illinois 60452, United States
    Recruiting
  • Mass Eye and Ear Infirmary Ophthalmology Clinical Research Office
    Boston, Massachusetts 02114, United States
    Withdrawn

    Not enrolling at this site.

  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02114, United States
    Recruiting
  • University of Michigan Kellog Eye Center
    Ann Arbor, Michigan 48105, United States
    Recruiting
  • Deep Blue Retina
    Southaven, Mississippi 38671, United States
    Recruiting
  • NJ Retina
    New Brunswick, New Jersey 08901, United States
    Withdrawn

    Not enrolling at this site.

  • Casey Eye Institute Oregon Health & Science University
    Portland, Oregon 97239, United States
    Recruiting
  • Mid-Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • Tennessee Retina, PC
    Nashville, Tennessee 37203, United States
    Withdrawn

    Not enrolling at this site.

  • Retina Foundation of the Southwest
    Dallas, Texas 75231, United States
    Recruiting
  • Valley Retina Institute
    McAllen, Texas 78503, United States
    Completed

    Not enrolling at this site.

  • University of Washington
    Seattle, Washington 98104, United States
    Withdrawn

    Not enrolling at this site.

  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
    Recruiting
09

References and documents

Related links

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2019 (actual). Primary completion is estimated for Dec 2027, 107 months after the start.

Of 13 phase 1 interventional studies under Geographic Atrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 107 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Jul 2018 → Jan 2019, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
Jun 6, 2017
StartActual
Jan 30, 2019was Jul 2018
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 13, 2018→Jan 30, 2019
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Jul 13, 2018→Jan 30, 2019
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03178149
Responsible party
Sponsor
First posted
Jun 6, 2017
Start date
Jan 30, 2019
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Astellas Institute for Regenerative Medicine
Contact
astellas.registration@astellas.com
800-888-7704
Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion